{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:54:56Z","timestamp":1790420096893,"version":"4.1.0"},"reference-count":157,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>RNA viruses have been subjected to substantial engineering efforts to support gene therapy applications and vaccine development. Typically, retroviruses, lentiviruses, alphaviruses, flaviviruses rhabdoviruses, measles viruses, Newcastle disease viruses, and picornaviruses have been employed as expression vectors for treatment of various diseases including different types of cancers, hemophilia, and infectious diseases. Moreover, vaccination with viral vectors has evaluated immunogenicity against infectious agents and protection against challenges with pathogenic organisms. Several preclinical studies in animal models have confirmed both immune responses and protection against lethal challenges. Similarly, administration of RNA viral vectors in animals implanted with tumor xenografts resulted in tumor regression and prolonged survival, and in some cases complete tumor clearance. Based on preclinical results, clinical trials have been conducted to establish the safety of RNA virus delivery. Moreover, stem cell-based lentiviral therapy provided life-long production of factor VIII potentially generating a cure for hemophilia A. Several clinical trials on cancer patients have generated anti-tumor activity, prolonged survival, and even progression-free survival.<\/jats:p>","DOI":"10.3390\/genes10030189","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T05:45:36Z","timestamp":1551678336000},"page":"189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["RNA Viruses as Tools in Gene Therapy and Vaccine Development"],"prefix":"10.3390","volume":"10","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2018). Viral Vectors in Gene Therapy. Diseases, 6.","DOI":"10.3390\/diseases6020042"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMra032207","article-title":"Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency","volume":"350","author":"McCormack","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Garrigue","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","article-title":"Dendritic cell-targeted vaccines","volume":"5","author":"Cohn","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"794528","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156652312800099599","article-title":"Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice","volume":"12","author":"Wang","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156652305774329285","article-title":"HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy","volume":"5","author":"Epstein","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.surg.2015.03.044","article-title":"Oncolytic gene therapy with recombinant vaccinia virus strain GLV-2b372 efficiently kills hepatocellular carcinoma","volume":"158","author":"Ady","year":"2015","journal-title":"Surgery"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-42934-2_2","article-title":"Retroviral vectors for cancer gene therapy","volume":"209","author":"Schambach","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1073\/pnas.81.20.6349","article-title":"High-efficiency gene transfer into mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range","volume":"81","author":"Cone","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/sj.gt.3301206","article-title":"Plat-E: an efficient and stable system for transient packaging of retroviruses","volume":"7","author":"Morita","year":"2000","journal-title":"Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/jvi.62.12.4828-4831.1988","article-title":"Influence of env and long terminal repeat sequences on the tissue tropism of avian leukosis viruses","volume":"62","author":"Brown","year":"1988","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0091-679X(08)60600-7","article-title":"Generation of high-titer pseudotyped retroviral vectors with very broad host range","volume":"43","author":"Yee","year":"1994","journal-title":"Methods Cell Biol."},{"key":"ref_16","first-page":"493","article-title":"Design of retroviral vectors and helper cells for gene therapy","volume":"52","author":"Hu","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gen. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hgtb.2017.086","article-title":"Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines","volume":"28","author":"Manceur","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.exphem.2006.02.005","article-title":"Lentiviral vectors pseudotyped with murine ecotropic envelope: Increased biosafety and convenience in preclinical research","volume":"34","author":"Schambach","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coph.2015.08.003","article-title":"Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells","volume":"24","author":"Verhoeyen","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12033-017-0006-y","article-title":"Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach","volume":"59","author":"Tokgun","year":"2017","journal-title":"Mol. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: Gene expression, replication and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/sj.gt.3302620","article-title":"Biology and applications of alphaviruses in gene therapy","volume":"12","author":"Lundstrom","year":"2005","journal-title":"Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","article-title":"A new generation of animal cell expression vectors based on the Semliki Forest virus replicon","volume":"9","author":"Liljestrom","year":"1991","journal-title":"Biotechnology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","article-title":"Sindbis virus: An efficient, broad host range vector for gene expression in animal cells","volume":"243","author":"Xiong","year":"1989","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/mt.2015.172","article-title":"Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1","volume":"24","author":"Li","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1073\/pnas.96.8.4598","article-title":"Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors","volume":"96","author":"Polo","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000215947","article-title":"Selection and characterization of packaging cell lines for XJ-160 virus","volume":"52","author":"Zhu","year":"2009","journal-title":"Intervirology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1517\/14712598.6.2.135","article-title":"Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications","volume":"6","author":"Pijlman","year":"2006","journal-title":"Exp. Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1128\/JVI.72.7.5967-5977.1998","article-title":"Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans","volume":"72","author":"Khromykh","year":"1998","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/viro.2002.1453","article-title":"Construction and characterization of subgenomic replicons of New York strain of West Nile virus","volume":"296","author":"Shi","year":"2002","journal-title":"Virology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11605","DOI":"10.1128\/JVI.78.21.11605-11614.2004","article-title":"Trans-packaged West Nile virus-like particles: Infectious properties in vitro and in infected mosquito vectors","volume":"78","author":"Scholle","year":"2004","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/JVI.77.2.1644-1648.2003","article-title":"Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins","volume":"77","author":"Molenkamp","year":"2003","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2004.10.034","article-title":"Construction and applications of yellow fever virus replicons","volume":"331","author":"Jones","year":"2005","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1128\/JVI.79.9.5414-5420.2005","article-title":"Dengue virus inhibits \u03b1 interferon signaling by reducing STAT2 expression","volume":"79","author":"Jones","year":"2005","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Pang, X., Zhang, M., and Dayton, A.I. (2001). Development of dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol., 1.","DOI":"10.1186\/1471-2180-1-28"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.77.16.8924-8933.2003","article-title":"Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line","volume":"77","author":"Gherke","year":"2003","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00705-003-0262-y","article-title":"Sub-genomic replicons of tick-borne encephalitis virus","volume":"149","author":"Hayasaka","year":"2004","journal-title":"Arch. Virol."},{"key":"ref_41","unstructured":"Knipe, D.M., and Howley, P.M. (2007). Rhabdoviridiae. Fields\u2019 Virology, Wolters Kluwer Health\/Lippincott Williams & Wilkins. [5th ed.]."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nprot.2013.094","article-title":"Design and generation of recombinant rabies virus vectors","volume":"8","author":"Osakada","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2012.11.007","article-title":"Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression","volume":"171","author":"An","year":"2013","journal-title":"Virus Res."},{"key":"ref_44","first-page":"513","article-title":"Vaccinia virus-free recovery of vesicular stomatitis virus","volume":"3","author":"Harty","year":"2001","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/neuro.05.001.2009","article-title":"Dual transneural tracing in the rat entorhoinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors","volume":"3","author":"Ohara","year":"2009","journal-title":"Front. Neuroanat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiol. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","article-title":"A recombinant measles virus expressing hepatitis B surface antigen induces humoral responses in genetically modified mice","volume":"73","author":"Singh","year":"1999","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kim, S.H., and Samal, S.K. (2016). Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines. Viruses, 8.","DOI":"10.3390\/v8070183"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant Newcastle Disease Virus as a Vaccine Vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1099\/vir.0.000142","article-title":"Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism","volume":"96","author":"Zhang","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1099\/vir.0.000067","article-title":"Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene","volume":"96","author":"Wen","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_53","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MHT-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_54","first-page":"307","article-title":"Systemic analysis of a novel coxsackievirus gene delivery system in a mouse model","volume":"19","author":"Kim","year":"2009","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1586\/14760584.7.10.1557","article-title":"Coxsackievirus B3 vaccines: Use as an expression vector for prevention of myocarditis","volume":"7","author":"Henke","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1073\/pnas.83.12.4552","article-title":"Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: A model for human gene therapy","volume":"83","author":"Kwok","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","first-page":"136","article-title":"Versatile retroviral vectors for potential use in gene therapy","volume":"1","author":"Hawley","year":"1994","journal-title":"Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hum.2014.100","article-title":"Intravenous administration of retroviral replicating vector, Toca 511, demonstrates efficacy in orthotopic immune-competent mouse glioma model","volume":"26","author":"Huang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s12325-017-0636-2","article-title":"A review of Chronic Granulomatous Disease","volume":"34","author":"Arnold","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4939-3684-7_17","article-title":"Gene Modification of Human Natural Killer Cells Using a Retroviral Vector","volume":"1441","author":"Kellner","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector","volume":"136","author":"Jackow","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/mt.2011.233","article-title":"Preclinical corrective gene transfer in xeroderma pigmentosium human skin stem cells","volume":"20","author":"Warrick","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/hgtb.2013.016","article-title":"Lentiviral vector-mediated RNA silencing in the central nervous system","volume":"25","author":"Hutson","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human \u03b1-synuclein in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jgm.1555","article-title":"Knockdown of GAD87 protein levels normalizes neuronal activity in a rat model of Parkinson\u2019s disease","volume":"13","author":"Horvath","year":"2011","journal-title":"J. Gene Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer\u2019s disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nat. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1523\/JNEUROSCI.3637-10.2010","article-title":"Silencing of CDK5 reduces neurofibrillary tangles in Alzheimer\u2019s mice","volume":"30","author":"Piedrahita","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.brainres.2017.05.018","article-title":"Lentivirus-mediated inhibition of AQP4 accelerates motor function recovery associated with NGF in spinal cord contusion rats","volume":"1669","author":"Chen","year":"2017","journal-title":"Brain Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2016.87","article-title":"Safe and efficient gene therapy of pyruvate kinase deficiency","volume":"24","author":"Calabria","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of \u03b2-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","article-title":"Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency","volume":"9","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14712598.2018.1425679","article-title":"Reprogramming T-cells for adoptive immunotherapy of ovarian cancer","volume":"18","author":"Genta","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhen, A., Peterson, C., Carrillo, M.A., Reddy, S.S., Youn, C.S., Lam, B.B., Chang, N.Y., Martin, H.A., Rick, J.W., and Kim, J. (2017). Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006753"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ringpis, G.E., Shimizu, S., Arokium, H., Camba-Col\u00f3n, J., Carroll, M.V., Cortado, R., Xie, Y., Kim, P.Y., Sahakyan, A., and Lowe, E.L. (2012). Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem\/progenitor cells in humanized BLT mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053492"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1038\/mtm.2016.7","article-title":"Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS","volume":"3","author":"Peterson","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2017). Oncolytic alphaviruses in cancer Immunotherapy. Vaccines, 5.","DOI":"10.3390\/vaccines5020009"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/ijc.23646","article-title":"Replication competent Semliki Forest virus prolongs survival in experimental lung cancer","volume":"123","author":"Ketola","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2990.2010.01110.x","article-title":"Semliki Forest virus-mediated gene therapy of the RG2 rat glioma","volume":"36","author":"Roche","year":"2010","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/JVI.01940-12","article-title":"Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting","volume":"87","author":"Ylosmaki","year":"2013","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","article-title":"Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein","volume":"75","author":"Wilson","year":"2001","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.1038\/s41598-018-31003-6","article-title":"DNA-launched RNA replicon vaccines induce potent anti-Ebola immune responses that can be further improved by a recombinant MVA boost","volume":"8","author":"Zusinaite","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2018). Self-replicating RNA Viruses for RNA Therapeutics. Molecules, 23.","DOI":"10.3390\/molecules23123310"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/aid.1998.14.1369","article-title":"Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles","volume":"14","author":"Brand","year":"1998","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.imlet.2017.08.019","article-title":"Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and pol RT genes","volume":"190","author":"Ajbani","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/viro.2000.0635","article-title":"Influenza virus (A\/HK\/156\/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses","volume":"278","author":"Dybing","year":"2000","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"Wang","year":"2018","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2008.169","article-title":"A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy","volume":"16","author":"Smeenk","year":"2009","journal-title":"Gene Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1084\/jem.20171093","article-title":"Zika virus has oncolytic activity against glioblastoma stem cells","volume":"214","author":"Zhu","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1016\/j.vaccine.2008.04.001","article-title":"Kunjin replicon-based simian immunodeficiency virus gag vaccines","volume":"26","author":"Anraku","year":"2008","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014\/2015 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1128\/JVI.02511-10","article-title":"Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism","volume":"85","author":"Muik","year":"2011","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kimpel, J., Urbiola, C., Koske, I., Tober, R., Banki, Z., Wollmann, G., and von Laer, D. (2018). The Oncolytic Virus VSV-GP is Effective against Malignant Melanoma. Viruses, 10.","DOI":"10.3390\/v10030108"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ijc.31556","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/vaccines3030503","article-title":"Immunogenic subviral particles displaying domain III of dengue 2 envelope protein vectored by measles virus","volume":"3","author":"Valle","year":"2015","journal-title":"Vaccines"},{"key":"ref_103","first-page":"1678","article-title":"The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection","volume":"12","author":"Hu","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1128\/JVI.00923-07","article-title":"A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against virus challenge","volume":"81","author":"Devaux","year":"2007","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.mt.6300105","article-title":"Epidermal growth factor receptor (EGFR)retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas","volume":"15","author":"Paraskevakou","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-006-9200-5","article-title":"A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer","volume":"99","author":"McDonald","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"24895","DOI":"10.18632\/oncotarget.4366","article-title":"A measles virus selectively blind to signalling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells","volume":"6","author":"Fujiyuki","year":"2015","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/cas.13064","article-title":"Measles virus selectively blind to signalling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells","volume":"107","author":"Awano","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pros.20857","article-title":"Engineered measles virus as a novel oncolytic therapy against prostate cancer","volume":"69","author":"Msaouel","year":"2009","journal-title":"Prostate"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(01)00617-6","article-title":"Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration","volume":"172","author":"Phuangsab","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7785\/tcrt.2012.500414","article-title":"Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model","volume":"14","author":"Niu","year":"2015","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1743-422X-11-84","article-title":"Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer","volume":"11","author":"Chai","year":"2014","journal-title":"Virol. J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-12 and TNF-related and apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Ther. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2017.02.042","article-title":"Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy","volume":"802","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e01386-18","DOI":"10.1128\/JVI.01386-18","article-title":"A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma","volume":"92","author":"Abdullahi","year":"2018","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/gt.2011.201","article-title":"Coxsackievirus B3 used as a gene therapy vector to express functional FGF2","volume":"19","author":"Kim","year":"2012","journal-title":"Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","article-title":"Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21","volume":"10","author":"Shafren","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","article-title":"Systemic targeting of metastatic human breast xenografts by Coxsackievirus A21","volume":"113","author":"Skelding","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10637-010-9614-0","article-title":"Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride","volume":"30","author":"Skelding","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Berry","year":"2008","journal-title":"Prostate"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase I trial of vocimagine amiroretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_123","unstructured":"(2019, March 01). A Phase 2\/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02414165."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/humc.2013.019","article-title":"From bench to bedside: Preclinical evaluation of a self-activating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease","volume":"24","author":"Stein","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene Therapy in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenleuleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/hae.13011","article-title":"State of the art: Gene therapy of haemophilia","volume":"22","author":"Spencer","year":"2016","journal-title":"Haemophilia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jgm.2769","article-title":"Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells","volume":"16","author":"Dodd","year":"2014","journal-title":"J. Gene Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/humc.2016.056","article-title":"Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson\u2019s Disease","volume":"27","author":"Stewart","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.3390\/v7082816","article-title":"CCR5 targeted cell therapy for HIV and prevention of viral escape","volume":"7","author":"Bodor","year":"2015","journal-title":"Viruses"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1073\/pnas.232688199","article-title":"Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5","volume":"100","author":"Qin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","unstructured":"(2019, March 01). An Adaptive Phase I\/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem\/Progenitor Cells Transduced With LVsh5\/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01734850."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase I trial on an alphavirus replicon vaccine for cytomegalovirus in CMV negative volunteers","volume":"28","author":"Bernstein","year":"2010","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/CVI.00258-12","article-title":"Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults","volume":"19","author":"Wecker","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-controlled trial of two vaccines to prevent ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Longini","year":"2015","journal-title":"Lancet"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"98","DOI":"10.15585\/mmwr.su6503a14","article-title":"Implementing an Ebola Vaccine Study\u2014Sierra Leone","volume":"65","author":"Widdowson","year":"2016","journal-title":"MMWR Suppl."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/jco.2008.26.15_suppl.5538","article-title":"Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)","volume":"26","author":"Galanis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_149","unstructured":"NCT00390299 (2019, January 22). Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme, Available online: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00390299."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-004-0602-0","article-title":"Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory","volume":"54","author":"Schirrmacher","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1610-0387.2003.02014.x","article-title":"Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease","volume":"1","author":"Voit","year":"2003","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","article-title":"Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract","volume":"9","author":"Liang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"P341","DOI":"10.1186\/2051-1426-3-S2-P341","article-title":"Phase I\/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients","volume":"3","author":"Pandha","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"P343","DOI":"10.1186\/2051-1426-3-S2-P343","article-title":"Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment","volume":"3","author":"Andtbacka","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2017-CT026","article-title":"Abstract CT026: Phase 1b study of intratumoral coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial","volume":"77","author":"Silk","year":"2017","journal-title":"Cancer Res."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/3\/189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:35:41Z","timestamp":1760186141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/3\/189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":157,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["genes10030189"],"URL":"https:\/\/doi.org\/10.3390\/genes10030189","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}